News - Genzyme, Pharmaceutical

Filter

Current filters:

GenzymePharmaceutical

Popular Filters

1 to 25 of 61 results

European neurologists expect Biogen Idec’s Tecfidera to be preferred MS drug

European neurologists expect Biogen Idec’s Tecfidera to be preferred MS drug

16-04-2014

Surveyed neurologists in France, Germany, Italy, Spain and the UK project that 16% of their diagnosed…

AubagioBiogen IdecChemistryCNS DiseasesEuropeGenzymeMajorPharmaceuticalPharmacologyPhysicianResearchSANTecfidera

UK researchers find pancreatic cancer potential for plerixafor

UK researchers find pancreatic cancer potential for plerixafor

06-01-2014

A possible new method for treating pancreatic cancer which enables the body’s immune system to attack…

GenzymeMozobilOncologyPharmaceuticalPlerixaforResearchSanofi

US FDA calls for more trials on Genzyme’s Lemtrada

US FDA calls for more trials on Genzyme’s Lemtrada

30-12-2013

There was a significant disappointment this morning for French drug major Sanofi, when it revealed that…

BayerGenzymeLemtradaNeurologicalNorth AmericaPharmaceuticalRegulationSanofiUSA

Sanofi’s Aubagio gains backing from UK’s NICE

Sanofi’s Aubagio gains backing from UK’s NICE

08-12-2013

In final draft guidance issued on Friday, the UK drugs watchdog the National Institute for Health and…

AubagioEuropeGenzymeNeurologicalPharmaceuticalPricingRegulationSanofiUK

Sanofi’s Lemtrada gets support from FDA advisory panel

Sanofi’s Lemtrada gets support from FDA advisory panel

14-11-2013

French drug major Sanofi (Euronext: SAN) has received support from a US Food and Drug Administration…

CNS DiseasesEuropeGenzymeLemtradaPharmaceuticalRegulationSanofi

Chronic kidney disease market to witness slight decline by 2017

Chronic kidney disease market to witness slight decline by 2017

12-11-2013

The value of the chronic kidney disease market could drop 2.5% between 2012 and 2017 due to the loss…

EuropeFinancialGenzymeMarkets & MarketingNephrology and HepatologyPharmaceuticalRenagelRenvelaUSAZemplar Capsules

Sanofi says 3rd-qtr profits down, but sees end to patent cliff period

Sanofi says 3rd-qtr profits down, but sees end to patent cliff period

30-10-2013

French drug major Sanofi this morning posted third-quarter 2013 results with a fall in profitability…

FinancialGenzymePharmaceuticalSanofi

Aubagio significantly reduced risk of new clinical relapse or MRI lesion in MS study

03-10-2013

French drug major Sanofi and its subsidiary Genzyme announced positive new data from the TOPIC study…

AubagioGenzymeNeurologicalPharmaceuticalResearchSanofi

UK's NICE calls for more information on MS treatment Aubagio

18-09-2013

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) is calling on Genzyme,…

AubagioBiotechnologyEuropeGenzymeNeurologicalPharmaceuticalPricingRegulationSanofi

Genzyme's MS drug Lemtrada approved in Europe

17-09-2013

French drug major Sanofi (Euronext: SAN) and its USA-based biotech subsidiary Genzyme revealed this morning…

AubagioBiotechnologyEuropeGenzymeLemtradaNeurologicalPharmaceuticalRegulationSanofi

Sanofi's MS drug Aubagio gains final European approval

02-09-2013

Following a positive recommendation from the European Medicines Agency's Committee for Medicinal Products…

AubagioBiotechnologyEuropeGenzymeNeurologicalPharmaceuticalRegulationSanofi

New Zealand to widen access for type 1 and type 3 Gaucher disease drug

07-08-2013

New Zealand's Pharmaceutical Management Agency PHARMAC has announced the approval of a proposal to widen…

Asia-PacificBiotechnologyCerezymeGenzymePharmaceuticalRare diseasesRegulationSanofi

Sanofi sees end to "patent cliff" doldrums, as it misses forecasts

01-08-2013

French drug major Sanofi (Euronext: SAN) posted second-quarter 2013 financial results this morning (August…

BiotechnologyFinancialGenzymePharmaceuticalSanofi

Generics take toll on Sanofi's 1st-qtr sales, with net profit down 33.5%

02-05-2013

French drug major Sanofi (Euronext: SAN) today (May 2) reported first-quarter 2013 financial results…

BiotechnologyFinancialGenzymePharmaceuticalSanofi

Sanofi's Aubagio delayed onset of clinically definite MS in TOPIC study

25-04-2013

French drug major Sanofi (Euronext: SAN) US biotech subsidiary Genzyme announced today positive top-line…

AubagioBiotechnologyGenzymeNeurologicalPharmaceuticalResearchSanofi

Sanofi and Transgene collaborate on immunotherapy treatments; NAS designation of Aubagio disputed

25-03-2013

Drug major Sanofi (Euronext: SAN) and fellow France-based biotech firm Transgene SA (NYSE-Euronext: TNG)…

AubagioBiotechnologyEuropeGenzymeImmunologicalsNeurologicalPharmaceuticalProductionRegulationSanofiTransgene

Growing US uptake of Genzyme's Aubagio at three months post-launch

07-03-2013

Some 34% of surveyed US neurologists have prescribed French drug major Sanofi (Euronext: SAN) subsidiary…

AubagioBiotechnologyGenzymeMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalSanofi

Genzyme's eliglustat meets endpoints in Ph III studies for Gaucher disease

18-02-2013

US biotech firm Genzyme, a subsidiary if French drug major Sanofi (Euronext: SAN) has released positive…

BiotechnologyeliglustatGenzymePharmaceuticalRare diseasesResearchSanofi

FDA clears Sanofi and Isis' Kynamro for inherited cholesterol disorder

30-01-2013

The US Food and Drug Administration yesterday approved Sanofi (Euronext: SAN) subsidiary Genzyme's orphan…

BiotechnologyCardio-vascularGenzymeIsis PharmaceuticalsKynamroNorth AmericaPharmaceuticalRare diseasesRegulationSanofi

Genzyme says Lemtrada sBLA for MS accepted by FDA; reports on Aubagio

28-01-2013

French drug major Sanofi (Euronext: SAN) US biotech subsidiary Genzyme says that the US Food and Drug…

AubagioBiotechnologyGenzymeLemtradaMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalRegulationSanofi

1 to 25 of 61 results

Back to top